Medical treatments, including jabs used for weight loss, are monitored in part using the Medicines and Healthcare products ...

Eli Lilly (NYSE: LLY) stock defied today's market downturn, rising 2.6% through 11:15 a.m. ET on the back of two positive ...

Compared to other diabetes medications, GLP-1 drugs like Ozempic were associated with a lower risk for depression in a recent ...

The FDA has resolved the shortage of Wegovy and Ozempic, but companies like Hims and Hers may halt sales of compounded ...

With Hims & Her's main source of growth set to be extinguished, Citi analysts said its full-year guidance appears ...

Welcoming a newborn is something many couples dream of doing, but it can get complicated when conceiving becomes a roadblock.

Hims & Hers on Monday released fourth-quarter results that disappointed on gross margin and sparked concerns about the future ...

FDA ends semaglutide shortage, impacting compounding pharmacies. Hims & Hers plans personalized versions while Olympia ...

Eli Lilly & Co. said Tuesday it's cutting the price of single-dose vials of its Zepbound treatment for diabetes and obesity for patients who have to pay for the drug themselves. It said it will also ...

Jonathan Van Ness is sharing details about their recent weight loss. “All right, I have a confession to make,” the “Queer Eye” star said in a recent TikTok video. “Yes, I am on a GLP-1, or a weight ...

Risk for pancreatitis was not elevated among users of tirzepatide relative to placebo, despite the presence of elevated pancreatic enzymes.

Patients report that GLP-1 drugs like Ozempic and Mounjaro reduce “food noise,” the constant mental chatter about eating.